Jaroslaw P Maciejewski
Overview
Explore the profile of Jaroslaw P Maciejewski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
367
Citations
11852
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lundgren S, Huuhtanen J, Keranen M, Feng X, Patel B, Ryland G, et al.
Sci Transl Med
. 2025 Feb;
17(787):eadl6758.
PMID: 40009697
Immune aplastic anemia (AA) is a life-threatening bone marrow failure disorder driven by an autoimmune T cell attack against hematopoietic stem and progenitor cells (HSPCs). However, the exact autoantigen targets...
2.
Gurnari C, Robin M, Ades L, Aljurf M, Almeida A, Duarte F, et al.
Blood
. 2025 Feb;
PMID: 39970324
For patients with myelodysplastic neoplasm/syndrome (MDS), allogeneic hematopoietic cell transplantation (allo-HCT) represents the only potentially curative treatment, capable of eradicating disease-related mutant hematopoietic cells and establishing normal donor hematopoiesis. Biologic-assignment...
3.
Fattizzo B, Gurnari C, Giammarco S, Ricchiuti A, Awada H, Bortolotti M, et al.
Am J Hematol
. 2025 Jan;
100(4):584-591.
PMID: 39878088
We retrospectively analyzed a large international cohort of 1113 patients with aplastic anemia to evaluate treatment choice and outcome in elderly patients as compared with a younger population. Overall, 319...
4.
Risitano A, de Castro C, Han B, Kulasekararaj A, Maciejewski J, Scheinberg P, et al.
Blood Adv
. 2025 Jan;
PMID: 39774762
Iptacopan, a first-in-class, oral, selective complement factor B inhibitor, demonstrated efficacy and safety as monotherapy in C5 inhibitor (C5i)-experienced (APPLY-PNH [NCT04558918]) and C5i-naive (APPOINT-PNH [NCT04820530]) patients with paroxysmal nocturnal hemoglobinuria...
5.
Guarnera L, Gurnari C, Bravo-Perez C, Durmaz A, Williams N, Awada H, et al.
Leukemia
. 2025 Jan;
39(3):748-751.
PMID: 39755843
No abstract available.
6.
Visconte V, Maciejewski J, Guarnera L
Semin Hematol
. 2024 Nov;
PMID: 39616024
The introduction of artificial intelligence (AI), and in particular machine learning (ML), has revolutionized biomedical research at the clinical level, a trend that also includes hematologic malignancies and myeloid neoplasia...
7.
Kawashima N, Gurnari C, Bravo-Perez C, Kubota Y, Pagliuca S, Guarnera L, et al.
Leukemia
. 2024 Nov;
39(2):451-459.
PMID: 39572711
Past studies described occasional patients with myeloid neoplasms (MN) and coexistent large granular lymphocytic leukemia (LGLL) or T-cell clonopathy of unknown significance (TCUS), which may represent expansion of myeloid clonal...
8.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Salit R, et al.
Blood Adv
. 2024 Nov;
9(4):797-807.
PMID: 39561372
The aim of our study was to analyze the potential survival benefit associated with hematopoietic stem cell transplantation (HSCT) according to clinicobiological scores, which incorporate mutation-enhanced international prognostic score system...
9.
Fattizzo B, Marchetti A, Bosi A, Gurnari C, Giannotta J, Pedone G, et al.
Blood Adv
. 2024 Nov;
9(3):488-495.
PMID: 39536292
Diagnostic boundaries between immune thrombocytopenia (ITP) and other thrombocytopenic states, such as thrombocytopenic myelodysplastic syndromes, may be difficult to establish, and the detection of somatic mutations by next-generation sequencing (NGS)...
10.
Wang Y, Wei C, Lin C, Gurnari C, Awada H, Benajiba L, et al.
Leukemia
. 2024 Oct;
39(1):144-154.
PMID: 39367172
In addition to high-molecular risk (HMR) mutations (ASXL1, EZH2, SRSF2, IDH, and U2AF1), lower JAK2V617F variant allele frequencies (VAF) have been demonstrated to be associated with poor prognosis of myelofibrosis...